Trial intelligence / Profile preview

Methotrexate prescribing strategy comparison in psoriasis

2007-007678-43Phase 3Active

Sponsor: Assistance publique - Hôpitaux de Paris
Start: Feb 2008
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3 trial of methotrexate in psoriasis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Cumulative methotrexate dose required to achieve PASI 75. Started Feb 2008; status: active.

Drugs

methotrexate

Conditions

psoriasis

Beyond the preview

Go deeper on 2007-007678-43.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-007678-43.